<DOC>
	<DOC>NCT00726505</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus</brief_summary>
	<brief_title>Renal Mechanism of Action/Splay vs. TmG</brief_title>
	<detailed_description />
	<criteria>Male and female subjects Age 18 to 65 years BMI 18 to 35 kg/m2 Healthy subjects and subjects with type 2 diabetes mellitus on 1 of the following therapies: diet, sulfonylurea, and/or metformin No evidence of impaired renal function Unwilling or unable to use an acceptable method of birth control Subjects with type 1 diabetes mellitus, heart disease, hepatic C or B Exposure to insulin Use of exclusionary concomitant medications Evidence of significant kidney disease or any other significant medical or psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>